Speakers

Expand/Collapse

Leonide Saad
President & CEO
Alkeus

Day One

Wednesday, October 20, 2020

4:45 pm | Panel Discussion: With Unprecedented Phase III Progress & Expected Regulatory Feedback on Submissions, What Direction is Provided for the Dry AMD/GA Field?

Track 2 Day 2 AM

12:00 pm | Targeting the Visual Cycle Through Vitamin A Modification

Sobha Sivaprasad
Professor & Consultant
Ophthalmologist Moorfields Eye Hospital

Arun Upadhyay
Vice President, Research & Development
Ocugen

Track 1 Day 1 PM 1

3:15 pm | Spotlight on OCU410- Novel Modifier Gene AMD

Malia Edwards
Assistant Professor, Wilmer Eye Institute
Johns Hopkins Medicine

Track 1 Day 1 PM 1

2:45 pm | Testing a Novel Therapeutic Approach in Two Rat Models with GA Features

Chad Jackson
Director, Preclinical Translational Research Program
Foundation Fighting Blindness

Day One

Wednesday, October 20, 2020

5:30 pm | Chair's Closing Remarks

8:45 am | Chair’s Opening Remarks

Day Two

Thursday, October 21, 2021

4:30 pm | Chair’s Closing Remarks

8:45 am | Chair’s Opening Remarks

Allen Ho
Wills Eye Hospital Attending Surgeon, Director of Retina Research and President
The Retina Society

Track 1 Day 1 PM 1

2:15 pm | Enhanced Surgical & Office Based Delivery of Gene Therapy

Ashwath Jayagopal
Executive Director, Discovery Medicine
Kodiak

Day One

Wednesday, October 20, 2020

4:45 pm | Panel Discussion: With Unprecedented Phase III Progress & Expected Regulatory Feedback on Submissions, What Direction is Provided for the Dry AMD/GA Field?

10:30 am | Panel Discussion: Emerging Treatments for Dry AMD & GA - Therapeutic Avenues, Clinical Trials & Future Directions

Baruch Kuppermann
Director, Co-Director, Professor & Chair - Ophthalmology
UC Irvine

Day One

Wednesday, October 20, 2020

4:45 pm | Panel Discussion: With Unprecedented Phase III Progress & Expected Regulatory Feedback on Submissions, What Direction is Provided for the Dry AMD/GA Field?

10:30 am | Panel Discussion: Emerging Treatments for Dry AMD & GA - Therapeutic Avenues, Clinical Trials & Future Directions

Day Two

Thursday, October 21, 2021

3:30 pm | Panel Discussion & Presentation: The Future Landscape of Dry-AMD Therapies

Brian Culley
Chief Executive Officer
Lineage Cell Therapeutics

Track 2 Day 2 AM

11:00 am | A Further Spotlight on OpRegen - A RPE Transplant for Dry AMD with GA

Chad Bigelow
Director of the NIBR Ophthalmology
Novartis

Track 1 Day 2 AM

11:00 am | Overcome Challenges in Developing In-Vivo Models for Dry-AMD

Christine Curcio
Professor, Ophthalmology & Director
Age-Related Maculopathy Histopathology Lab, University of Alabama at Birmingham

Day Two

Thursday, October 21, 2021

9:00 am | Targeting Lipids in Early & Intermediate AMD by the Oil Spill Strategies

Claire Mitchell
Professor of Anatomy & Cell Biology, Department: Anatomy & Cell Biology
University of Pennsylvania

Pre-Conference Focus Day

October 19 2021

12:20 pm | Panel Discussion/Group Q&A

11:05 am | Discuss Pharmacological & Nanoparticle Approaches to Clearing Waste Accumulations from RPE Cells

Clark Tedford
Chief Executive Officer
LumiThera

Track 2 Day 1 PM 1

3:15 pm | Progress on the Development of Photobiomodulation (PBM) for the Treatment of Ocular Damage & Disease

Cyndy Grosskreutz
Global Head of NIBR Ophthalmology
Novartis

Day One

Wednesday, October 20, 2020

4:45 pm | Panel Discussion: With Unprecedented Phase III Progress & Expected Regulatory Feedback on Submissions, What Direction is Provided for the Dry AMD/GA Field?

10:30 am | Panel Discussion: Emerging Treatments for Dry AMD & GA - Therapeutic Avenues, Clinical Trials & Future Directions

Dhaval Desai
Senior Vice-President & Chief Development Officer
IVERIC Bio

Day One

Wednesday, October 20, 2020

9:30 am | Spotlight on Zimura - A C5 Inhibitor for GA

Goldis Malek
Associate Professor, Depts of Ophthalmology & Pathology
Duke University, Albert Eye Research Institute

Pre-Conference Focus Day

October 19 2021

11:55 am | Targeting Lipid Dysregulation & Inflammation as Potential Therapy for Early Dry- AMD

12:20 pm | Panel Discussion/Group Q&A

Grant Blouse
Chief Scientific Officer
Catalyst Bio

Track 1 Day 1 AM

11:45 am | Spotlight on CB 2782-PEG - A Complement Factor C3- Inactivating Protease for Dry AMD

Jane Hughes
CSO
Gyroscope Therapeutics

Track 2 Day 1 PM 1

2:15 pm | Optimize the Potential for CFI Based Gene Therapy in GA

Jane Lebkowski
President
Regenerative Patch Technologies

Track 2 Day 2 AM

11:30 am | Spotlight on Phase 1/2a Clinical Trial of a Bio-Engineered Implant for GA

Jeffrey Heier
Director, Retina Service Director
Ophthalmic Consultants of Boston (OCB)

Day Two

Thursday, October 21, 2021

3:30 pm | Panel Discussion & Presentation: The Future Landscape of Dry-AMD Therapies

Janet Sunness
Medical Director
Hoover Low Vision Services, Greater Baltimore Medical Center

Pre-Conference Focus Day

October 19 2021

2:00 pm | Review the Long-Term Natural History of Geographic Atrophy

John Ash
Professor of Ophthalmology
University of Florida

Pre-Conference Focus Day

October 19 2021

12:20 pm | Panel Discussion/Group Q&A

10:25 am | Explore How the Interlinked Metabolism between Photoreceptors & RPE is a Mechanism for Dry-AMD Progression, & a Target for Therapeutic Intervention

Josh Dunaief
Adele Niessen Professor of Ophthalmology, FM Kirby Center for Molecular Ophthalmology Scheie Eye Institute
University of Pennsylvania

Pre-Conference Focus Day

October 19 2021

12:20 pm | Panel Discussion/Group Q&A

10:00 am | Examine Iron-induced Oxidative Stress & Inflammation in a New Mouse Model of GA

Justis Ehlers
Associate Professor of Ophthalmology
Cleveland Clinic Lerner College of Medicine

Track 2 Day 2 PM

2:30 pm | Opportunities for Personalized Medicine - Automated Risk Classification for Progression in AMD & Utilizing Machine Learning Enhanced OCT Feature Extraction

Karsten Schmidt
Senior Vice President, Ophthalmology
Retrotope

Track 1 Day 2 AM

12:00 pm | Breaking the Vicious Circle of AMD Progression with Oxidation-Resistant DHA

Ralf Hornig
Director of Clinical Affairs
Pixum Vision

Day Two

Thursday, October 21, 2021

9:30 am | Spotlight on The Prima Bionic Vision System: Improving Visual Acuity in Patients with Advanced Dry AMD

Lukas Scheibler
Chief Innovation Officer
Apellis

Day One

Wednesday, October 20, 2020

10:00 am | The Role of Complement in Dry-AMD

Matt Feinsod
EVP of Global Strategy and Development
Applied Genetic Technologies Corporation (AGTC)

Track 1 Day 1 PM 1

1:45 pm | Leverage CFH Gene Therapy for Dry AMD

Michael Engles
Associate Director Biological Research
Abbvie

Track 1 Day 2 AM

11:30 am | Discuss a Novel Animal Model of GA that is Translatable to Human Disease

Michael McCaleb
Vice President, Clinical Development, & Head of Ophthalmology Disease Franchise
Ionis Pharmaceuticals

Track 2 Day 1 AM

12:15 pm | Spotlight on IONIS-FB-LRx – Systemic Administration of a RNA-Targeting Therapeutic for GA

Nadia Waheed
CMO
Gyroscope Therapeutics

Track 2 Day 2 PM

2:00 pm | Enhance Novel Clinical Trial Endpoints for Trials in GA

Paul Ashton
President & CEO
Inflammasome Therapeutics

Track 1 Day 2 PM

2:30 pm | How do Inflammasomes, Key Molecular Regulators, Play a Vital Role in Dry AMD?

Pete Coffey
Professor Rescue, Repair and Regeneration and Co-Director, Center for Stem Cell Biology and Engineering
UCL - Institute of Ophthalmology/Moorfields Eye Hospital and UC Santa Barbara

Pre-Conference Focus Day

October 19 2021

12:20 pm | Panel Discussion/Group Q&A

11:30 am | An Exclusive Look at RPE Transplantation for Age-related Macular Degeneration: The London Experience

Peter Kaiser
Professor of Ophthalmology
Cleveland Clinic Lerner College of Medicine

Day One

Wednesday, October 20, 2020

9:00 am | Opening Keynote: An Analysis of the Current Landscape of Dry-AMD Therapeutic Development - How to Overcome Current Regulatory & Clinical Hurdles to Moving Promising Agents to the Clinic

Jeff Willis
Senior Medical Director
Genentech

Track 1 Day 2 PM

2:00 pm | Spotlight on GR39821- Phase 1 Single & Multiple-Dose Safety Study of Anti-High Temperature Requirement A1 (HtrA1) in GA

Pravin Dugel
President
IVERIC Bio

Track 1 Day 2 PM

1:30 pm | On the Horizon - HtrA1 Inhibition in the Treatment of GA

Reenie McCarthy
Director, President & Chief Executive Officer
Stealth BioTherapeutics

Track 2 Day 1 PM 1

2:45 pm | Enhance Mitochondrial Health & Visual Acuity in Dry AMD

Sam Barone
CMO
Gemini Therapeutics

Track 2 Day 1 PM 1

1:45 pm | Spotlight on GEM103 - Restoring Physiologic Complement Activity with Complement Factor H (CFH) for GA

Sergio Leal
Director, Global Clinical Leader Ophthalmology
Bayer

Day Two

Thursday, October 21, 2021

10:00 am | Defining Visual Impairment and Clinically Relevant Endpoints in Intermediate AMD: The MACUSTAR Project

Shelley Boyd
Chief Executive Officer
Translatum Medicus

Track 1 Day 1 AM

12:15 pm | Optimize Macrophage Modulation for Late Nonexudative Dry AMD

SriniVas Sadda
Professor of Ophthalmology
UCLA

Track 2 Day 2 PM

1:30 pm | Optimize Novel Imaging Biomarkers & Endpoints for Dry AMD Trials

Donald Fong
Vice President, Ophthalmology Clinical Development
Annexon Biosciences

Track 2 Day 1 AM

11:45 am | Spotlight on ANX007 - Inhibition of C1q for GA

Vicken Karageozian
Chief Executive Officer
Allegro Ophthalmics

Day One

Wednesday, October 20, 2020

4:15 pm | Explore Oxidative Stress Regulating Therapy with Risuteganib in Dry-AMD

Victor Chong
Global Head of Retina, R&D
Janssen